Accurate understanding of tumor characteristics
Information at the molecular level helps medical teams gain a deeper understanding of tumor characteristics.
Each patient’s tumor biology and physical condition may be different.
Personalized analysis, through advanced testing technology, provides medical teams with more information,
helping to explore more suitable health management directions and follow-up plans.
Clinical Outcomes
Multiple clinical studies suggest that personalized cancer treatment strategies based on precision medicine may deliver meaningful clinical benefits across different cancer types, including improved response rates, extended progression-free survival, and better overall outcomes in high-risk or difficult-to-treat cases.
Extended Progression-Free Survival
In selected advanced cancer studies, patients receiving precision strategies showed a progression-free survival of approximately 23 weeks compared to 12 weeks with conventional approaches.
Improved Treatment Response Rate
Personalized treatment strategies combined with multi-modality approaches may significantly improve response rates, particularly in cases where conventional therapies show limited effectiveness.
Improved Outcomes in High-Risk Pediatric Cancers
Studies indicate that in high-risk pediatric tumors, two-year progression-free survival improved from approximately 12% to 26%.
Overall Improvement in Long-Term Survival Rates
Over the past decades, global cancer survival rates have steadily improved. Advances in diagnostic technologies, targeted therapies, immunotherapy, and precision medicine strategies are considered key contributors to improved outcomes.
Precision Medicine in High-Risk Pediatric Cancers
- Treatment response rate: ~36%
- Two-year progression-free survival: 26% (vs 12% control group)
- Highlights the potential value of precision oncology in pediatric tumors
Functional Precision Medicine in Relapsed/Refractory Pediatric Cancer
- Progression-free rate up to 83%
- Demonstrates clinical application in relapsed cases
WINTHER Study: Genomic and Transcriptomic Profiling
- ~26% of patients achieved disease stabilization or improvement
- Supports the role of gene-guided therapy in precision medicine
Precision Combination Therapy in Cancer Treatment
- Response rate: 50% (vs 22% control group)
- Demonstrates the advantage of personalized multi-drug strategies
Clinical Benefits in Refractory Cancer Patients
- Clinical benefit rate: 43% (vs 5% control group)
- Progression-free survival: 86 days vs 49 days
Contact our professional team to learn more about our liquid biopsy services.
What are the potential benefits for you?
It helps identify care options that may be more suitable for your specific cancer characteristics, thus supporting better treatment outcomes; it also helps reduce unnecessary physical burden and side effects caused by unsuitable care plans.
Medical Disclaimer:
The information provided in this article is for educational and reference purposes only and does not constitute medical advice or be used as a substitute for professional medical diagnosis, treatment, or advice. ALWAYS CONSULT ANY QUESTIONS YOU MAY HAVE ABOUT YOUR MEDICAL CONDITION OR MEDICAL PROBLEM THAT YOU HAVE ALWAYS CONSULT YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH PROFESSIONAL. The content of this article is not intended to recommend any specific test, treatment, or medication and should not be construed as such. If you develop symptoms or require medical assistance, please contact a healthcare professional promptly.